LPL Financial
XLO icon

LPL Financial’s Xilio Therapeutics XLO Stock Holding History

LPL Financial’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$13.4K – 6176
2025
Q4 		$13.4K Sell
1,500
-714
-32% -$7.5K ﹤0.01% 5840
2025
Q3 		$26.1K Hold
2,214
– – ﹤0.01% 5714
2025
Q2 		$21.1K Buy
+2,214
New +$23.4K ﹤0.01% 5468

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial's XLO Position: Q1 2026 in Review

LPL Financial sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 1,500 shares — an estimated $13.4K sold.

LPL Financial first reported a position in XLO in Q2 2025 and held it in 3 quarters. The position peaked at $26.1K in Q3 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • LPL Financial reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • LPL Financial sold 1,500 Xilio Therapeutics shares in Q1 2026, an estimated $13.4K.
  • LPL Financial first reported a position in Xilio Therapeutics in Q2 2025 and held it in 3 quarters.
  • LPL Financial's Xilio Therapeutics position peaked at $26.1K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.